BRPI0906556A2 - Composto, e, composição farmacêutica - Google Patents
Composto, e, composição farmacêuticaInfo
- Publication number
- BRPI0906556A2 BRPI0906556A2 BRPI0906556-3A BRPI0906556A BRPI0906556A2 BR PI0906556 A2 BRPI0906556 A2 BR PI0906556A2 BR PI0906556 A BRPI0906556 A BR PI0906556A BR PI0906556 A2 BRPI0906556 A2 BR PI0906556A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2320708P | 2008-01-24 | 2008-01-24 | |
| EP08001308 | 2008-01-24 | ||
| PCT/EP2009/050719 WO2009092764A1 (en) | 2008-01-24 | 2009-01-22 | Compounds comprising a cyclobutoxy group |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0906556A2 true BRPI0906556A2 (pt) | 2015-07-07 |
Family
ID=39490075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0906556-3A BRPI0906556A2 (pt) | 2008-01-24 | 2009-01-22 | Composto, e, composição farmacêutica |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100292188A1 (pt) |
| EP (1) | EP2238144A1 (pt) |
| JP (1) | JP2011510044A (pt) |
| KR (1) | KR20100121629A (pt) |
| CN (1) | CN101925606A (pt) |
| AR (1) | AR070234A1 (pt) |
| AU (1) | AU2009207693A1 (pt) |
| BR (1) | BRPI0906556A2 (pt) |
| CA (1) | CA2710474A1 (pt) |
| CO (1) | CO6321170A2 (pt) |
| DO (1) | DOP2010000229A (pt) |
| EA (1) | EA201001205A1 (pt) |
| IL (1) | IL206404A0 (pt) |
| MX (1) | MX2010007587A (pt) |
| NZ (1) | NZ586399A (pt) |
| PE (1) | PE20091883A1 (pt) |
| UY (1) | UY31611A1 (pt) |
| WO (1) | WO2009092764A1 (pt) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090024811A (ko) | 2006-06-23 | 2009-03-09 | 아보트 러보러터리즈 | 히스타민 ｈ3 수용체 조절제로서의 사이클로프로필 아민 유도체 |
| US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| WO2010114971A1 (en) * | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| UY33027A (es) * | 2009-11-13 | 2011-06-30 | Astrazeneca Ab | Pirazina sustituida con oxazolo[4,5-c]piridina |
| TWI522361B (zh) * | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TWI543984B (zh) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| USRE48301E1 (en) | 2010-07-09 | 2020-11-10 | Abbvie B.V. | Fused heterocyclic derivatives as S1P modulators |
| US8912179B2 (en) * | 2010-09-02 | 2014-12-16 | Suven Life Sciences Limited | Heterocyclyl compounds as histamine H3 receptor ligands |
| WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2013076590A1 (en) | 2011-11-23 | 2013-05-30 | Oxygen Healthcare Research Pvt. Ltd | Benzothiazine compounds as h3 receptor ligands |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| IL289834B1 (en) | 2012-06-13 | 2024-03-01 | Incyte Holdings Corp | Conversion of tricyclic compounds as FGFR inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| NZ718430A (en) | 2013-10-04 | 2021-12-24 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| EA201691872A1 (ru) | 2014-03-19 | 2017-04-28 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств |
| CN104059028B (zh) * | 2014-06-06 | 2020-10-16 | 北京智博高科生物技术有限公司 | 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用 |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AU2015360416A1 (en) | 2014-12-10 | 2017-06-08 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN114230571A (zh) | 2015-09-14 | 2022-03-25 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| RU2018132559A (ru) | 2016-02-16 | 2020-03-17 | Массачусетс Инститьют Оф Текнолоджи | Связывающие молекулы для max в качестве модуляторов myc и их применения |
| CN109153644B (zh) | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
| EP3788047A2 (en) | 2018-05-04 | 2021-03-10 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| CA3099655A1 (en) * | 2018-05-08 | 2019-11-14 | Nippon Shinyaku Co., Ltd. | Azabenzimidazole compounds and pharmaceutical |
| EA202190248A1 (ru) | 2018-07-11 | 2021-06-16 | Х. Ли Моффитт Кэнсер Сентер Энд Рисерч Инститьют, Инк. | Димерные иммуномодулирующие соединения против механизмов на основе цереблона |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| BR112022007163A2 (pt) | 2019-10-14 | 2022-08-23 | Incyte Corp | Heterociclos bicíclicos como inibidores de fgfr |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN114728982A (zh) | 2019-10-31 | 2022-07-08 | 逃逸生物有限公司 | 固体形式的s1p-受体调节剂 |
| US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| WO2021247969A1 (en) | 2020-06-05 | 2021-12-09 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008534542A (ja) * | 2005-03-31 | 2008-08-28 | ユセベ ファルマ ソシエテ アノニム | オキサゾール部分又はチアゾール部分を含む化合物、それらの製造方法及びそれらの使用 |
| US7553964B2 (en) * | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
| US7576110B2 (en) * | 2005-09-22 | 2009-08-18 | Abbott Laboratories | Benzothiazole cyclobutyl amine derivatives |
-
2009
- 2009-01-22 US US12/812,719 patent/US20100292188A1/en not_active Abandoned
- 2009-01-22 PE PE2009000073A patent/PE20091883A1/es not_active Application Discontinuation
- 2009-01-22 WO PCT/EP2009/050719 patent/WO2009092764A1/en active Application Filing
- 2009-01-22 EA EA201001205A patent/EA201001205A1/ru unknown
- 2009-01-22 CN CN2009801029945A patent/CN101925606A/zh active Pending
- 2009-01-22 KR KR1020107018823A patent/KR20100121629A/ko not_active Application Discontinuation
- 2009-01-22 NZ NZ586399A patent/NZ586399A/en not_active IP Right Cessation
- 2009-01-22 JP JP2010543497A patent/JP2011510044A/ja not_active Withdrawn
- 2009-01-22 BR BRPI0906556-3A patent/BRPI0906556A2/pt not_active IP Right Cessation
- 2009-01-22 MX MX2010007587A patent/MX2010007587A/es not_active Application Discontinuation
- 2009-01-22 AU AU2009207693A patent/AU2009207693A1/en not_active Abandoned
- 2009-01-22 EP EP09703770A patent/EP2238144A1/en not_active Withdrawn
- 2009-01-22 CA CA2710474A patent/CA2710474A1/en not_active Abandoned
- 2009-01-23 UY UY031611A patent/UY31611A1/es unknown
- 2009-01-23 AR ARP090100203A patent/AR070234A1/es unknown
-
2010
- 2010-06-16 IL IL206404A patent/IL206404A0/en unknown
- 2010-07-09 CO CO10083721A patent/CO6321170A2/es not_active Application Discontinuation
- 2010-07-23 DO DO2010000229A patent/DOP2010000229A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL206404A0 (en) | 2010-12-30 |
| KR20100121629A (ko) | 2010-11-18 |
| WO2009092764A1 (en) | 2009-07-30 |
| NZ586399A (en) | 2011-12-22 |
| CN101925606A (zh) | 2010-12-22 |
| JP2011510044A (ja) | 2011-03-31 |
| MX2010007587A (es) | 2010-08-04 |
| EA201001205A1 (ru) | 2011-04-29 |
| EP2238144A1 (en) | 2010-10-13 |
| DOP2010000229A (es) | 2010-08-31 |
| AR070234A1 (es) | 2010-03-25 |
| UY31611A1 (es) | 2009-08-31 |
| PE20091883A1 (es) | 2010-01-07 |
| US20100292188A1 (en) | 2010-11-18 |
| CO6321170A2 (es) | 2011-09-20 |
| CA2710474A1 (en) | 2009-07-30 |
| AU2009207693A1 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2140867I2 (lt) | Farmacinė kompozicija | |
| LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
| BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI1010772A2 (pt) | composto,e, composição farmacêutica. | |
| BRPI0917681A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0721651A2 (pt) | Composição farmacêutica | |
| BRPI0920521A2 (pt) | combinação farmacêutica | |
| BRPI0715712A2 (pt) | Composição farmacêutica | |
| BRPI0719393A2 (pt) | Composição farmacêutica | |
| BRPI0812354A2 (pt) | Composição farmacêutica não-aquosa. | |
| DK2120884T3 (da) | Farmaceutisk sammensætning | |
| IT1392101B1 (it) | Composizione comprendente isoflavoni | |
| DK2285413T3 (da) | Farmaceutisk sammensætning | |
| DK2254873T3 (da) | Benzodiazepinforbindelse og farmaceutisk sammensætning. | |
| BRPI0719398A2 (pt) | Composição farmacêutica. | |
| BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
| BRPI0720234A2 (pt) | Composição farmacêutica | |
| BRPI0905369A2 (pt) | Composição farmacêutica, composição e kit compartimentado | |
| BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
| BR112012000831A2 (pt) | compostos, composições farmacêuticas e métodos relacionados | |
| BRPI0921313A2 (pt) | composição farmaucêutica | |
| DK2285357T3 (da) | Farmaceutisk sammensætning omfattende brivaracetam | |
| BRPI0912118A2 (pt) | composto, composição farmacêutica, e, intermediário sintético | |
| BRPI0914182A2 (pt) | composto, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |